Oramed Pharmaceuticals (ORMP) Short Interest Ratio & Short Volume $2.37 -0.12 (-4.82%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Oramed Pharmaceuticals Short Interest DataOramed Pharmaceuticals (ORMP) has a short interest of 299,500 shares. This marks a -4.59% decrease in short interest from the previous month. The short interest ratio (days to cover) is 2.4, indicating that it would take 2.4 days of the average trading volume of 139,352 shares to cover all short positions.Current Short Interest299,500 sharesPrevious Short Interest313,900 sharesChange Vs. Previous Month-4.59%Dollar Volume Sold Short$709,815.00Short Interest Ratio2.4 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares40,312,000 sharesPercentage of Shares Shorted0.74%Today's Trading Volume100,535 sharesAverage Trading Volume139,352 sharesToday's Volume Vs. Average72% Short Selling Oramed Pharmaceuticals? Sign up to receive the latest short interest report for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartORMP Short Interest Over TimeORMP Days to Cover Over TimeORMP Percentage of Float Shorted Over Time Ad Brownstone ResearchMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. Oramed Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/2024299,500 shares $709,815.00 -4.6%N/A2.4 $2.37 11/15/2024313,900 shares $699,997.00 +4.6%N/A3.1 $2.23 10/31/2024300,000 shares $714,000.00 +0.5%N/A3 $2.38 10/15/2024298,500 shares $701,475.00 -12.3%N/A3 $2.35 9/30/2024340,400 shares $830,576.00 -4.0%N/A3.4 $2.44 9/15/2024354,400 shares $882,456.00 -2.4%N/A2.9 $2.49 Get the Latest News and Ratings for ORMP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/31/2024363,200 shares $868,048.00 +53.0%N/A2.7 $2.39 8/15/2024237,400 shares $557,890.00 -14.6%N/A1.7 $2.35 7/31/2024278,100 shares $709,155.00 -16.9%N/A2.1 $2.55 7/15/2024334,700 shares $846,791.00 -36.7%N/A2.7 $2.53 6/30/2024529,100 shares $1.36 million +13.1%N/A4 $2.57 6/15/2024467,800 shares $1.05 million +63.3%N/A4 $2.25 5/31/2024286,500 shares $624,570.00 -5.9%N/A2.6 $2.18 5/15/2024304,600 shares $727,994.00 -6.2%N/A2.5 $2.39 4/30/2024324,600 shares $753,072.00 -11.7%N/A2.2 $2.32 4/15/2024367,600 shares $889,592.00 -37.0%N/A2.2 $2.42 3/31/2024583,900 shares $1.70 million +20.6%N/A3.3 $2.92 3/15/2024484,000 shares $1.41 million -3.3%N/A2.6 $2.92 2/29/2024500,700 shares $1.65 million -27.6%N/A2.5 $3.29 2/15/2024691,600 shares $2.17 million +76.0%N/A3.6 $3.14 1/31/2024393,000 shares $1.18 million +5.3%N/A2.1 $3.00 1/15/2024373,200 shares $873,288.00 +17.4%N/A1.8 $2.34 12/31/2023318,000 shares $734,580.00 -15.4%N/A1.6 $2.31 12/15/2023376,000 shares $827,200.00 -10.0%N/A2 $2.20 11/30/2023417,800 shares $927,516.00 -10.3%N/A2.4 $2.22 11/15/2023465,900 shares $959,754.00 +3.6%N/A2.6 $2.06 10/31/2023449,800 shares $823,134.00 -23.6%N/A2.5 $1.83 10/15/2023588,400 shares $1.28 million -2.2%N/A3.5 $2.18 9/30/2023601,800 shares $1.57 million +6.3%N/A3.4 $2.61 9/15/2023566,200 shares $1.72 million +25.8%N/A2.8 $3.04 8/31/2023450,000 shares $1.48 million -13.7%N/A1.8 $3.28 8/15/2023521,600 shares $1.63 million +4.0%N/A1.4 $3.13 7/31/2023501,400 shares $1.70 million -25.9%N/A0.6 $3.39 7/15/2023677,000 shares $2.17 million -15.1%N/A0.8 $3.21 6/30/2023797,800 shares $2.86 million -6.5%N/A0.9 $3.58 6/15/2023852,900 shares $3.45 million -7.6%N/A0.9 $4.04 5/31/2023923,300 shares $3.73 million +89.9%N/A1 $4.04 5/15/2023486,300 shares $1.52 million -6.6%N/A0.5 $3.13 4/30/2023520,400 shares $1.18 million -33.4%N/A0.7 $2.27 4/15/2023781,200 shares $1.75 million -1.0%N/A0.9 $2.24Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. 3/31/2023789,300 shares $1.72 million -19.9%N/A0.5 $2.18 3/15/2023985,700 shares $1.99 million -7.0%N/A0.6 $2.02 2/28/20231,060,000 shares $2.23 million +8.3%N/A0.6 $2.10 2/15/2023978,500 shares $2.15 million +3.4%N/A0.6 $2.20 1/31/2023946,000 shares $1.88 million -65.6%N/A0.6 $1.99 1/15/20232,750,000 shares $6.19 million -2.5%N/A2.1 $2.25 12/30/20222,820,000 shares $33.92 million +4.8%N/A6.9 $12.03 12/15/20222,690,000 shares $22.00 million -2.2%N/A9.1 $8.18 11/30/20222,750,000 shares $23.24 million -5.5%N/A10.5 $8.45 11/15/20222,910,000 shares $26.19 million -3.6%N/A10.9 $9.00 10/31/20223,020,000 shares $21.47 million +0.7%N/A11 $7.11 10/15/20223,000,000 shares $18.72 million -3.2%N/A9.4 $6.24 9/30/20223,100,000 shares $20.09 million +4.7%N/A3.7 $6.48 9/15/20222,960,000 shares $24.92 million -0.3%N/A2.3 $8.42 8/31/20222,970,000 shares $25.42 million -0.7%N/A2.2 $8.56 8/15/20222,990,000 shares $29.63 million -6.9%N/A2.1 $9.91 7/31/20223,210,000 shares $28.18 million -10.6%N/A2.1 $8.78 7/15/20223,590,000 shares $28.65 million +30.1%N/A2.3 $7.98 6/30/20222,760,000 shares $12.64 million -25.4%N/A1.8 $4.58 6/15/20223,700,000 shares $14.65 million +12.8%30.1%4.7 $3.96 5/31/20223,280,000 shares $15.19 million +1.6%N/A5.1 $4.63 5/15/20223,230,000 shares $14.76 million +26.2%N/A5.3 $4.57 4/30/20222,560,000 shares $13.16 million +15.8%N/A4.8 $5.14 4/15/20222,210,000 shares $15.16 million -6.8%N/A3.6 $6.86 3/31/20222,370,000 shares $20.50 million +4.9%N/A3.8 $8.65 3/15/20222,260,000 shares $20.05 million +2.7%N/A3.1 $8.87 2/28/20222,200,000 shares $22.66 million -2.2%N/A2.8 $10.30 2/15/20222,250,000 shares $26.15 million +2.3%N/A2.5 $11.62 1/31/20222,200,000 shares $19.71 million +9.5%N/A2.3 $8.96 1/15/20222,010,000 shares $22.21 million -9.1%N/A2.2 $11.05 12/31/20212,210,000 shares $31.56 million +10.0%N/A2.6 $14.28 12/15/20212,010,000 shares $30.33 million +122.9%N/A2.5 $15.09 11/30/2021901,600 shares $17.33 million -3.4%N/A1.1 $19.22 11/15/2021933,400 shares $26.28 million -3.5%N/A1.2 $28.16 10/29/2021967,400 shares $22.65 million -7.9%N/A1.2 $23.41 10/15/20211,050,000 shares $23.16 million -3.7%3.7%1.3 $22.06 9/30/20211,090,000 shares $23.96 million -2.7%3.8%1.2 $21.98 9/15/20211,120,000 shares $21.78 million -5.9%3.9%1.3 $19.45 8/31/20211,190,000 shares $23.42 million -13.8%4.2%1.5 $19.68 8/13/20211,380,000 shares $24.40 million -27.8%4.9%1.8 $17.68 7/30/20211,910,000 shares $27.10 million -14.7%6.9%2.8 $14.19 7/15/20212,240,000 shares $28.45 million -6.3%8.1%4.1 $12.70 6/30/20212,390,000 shares $31.98 million +10.7%8.9%4.7 $13.38 6/15/20212,160,000 shares $28.84 million -12.9%8.0%4.7 $13.35 5/28/20212,480,000 shares $28.57 million -0.8%9.6%3.8 $11.52 5/14/20212,500,000 shares $25.65 million +7.3%9.7%4 $10.26 4/30/20212,330,000 shares $25.33 million +4.5%9.1%3.4 $10.87 4/15/20212,230,000 shares $20.69 million +0.5%8.7%2.6 $9.28 3/31/20212,220,000 shares $22.44 million +22.7%9.0%2.7 $10.11 3/15/20211,810,000 shares $17.01 million +4.0%7.4%2.2 $9.40Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. 2/26/20211,740,000 shares $15.57 million -4.4%7.1%2.6 $8.95 2/12/20211,820,000 shares $18.56 million +45.6%7.6%2 $10.20 1/29/20211,250,000 shares $8.74 million +54.8%5.3%1.5 $7.00 1/15/2021807,700 shares $3.60 million No Change3.8%1.3 $4.46 1/31/2020442,300 shares $2.31 million -1.4%3.3%2 $5.23 1/15/2020442,300 shares $2.34 million -1.4%3.3%2 $5.28 12/31/2019448,700 shares $2.35 million -23.5%3.3%2.1 $5.23 ORMP Short Interest - Frequently Asked Questions What is Oramed Pharmaceuticals' current short interest? Short interest is the volume of Oramed Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 299,500 shares of ORMP short. Learn More on Oramed Pharmaceuticals' current short interest. What is a good short interest ratio for Oramed Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ORMP shares currently have a short interest ratio of 2.0. Learn More on Oramed Pharmaceuticals's short interest ratio. Is Oramed Pharmaceuticals' short interest increasing or decreasing? Oramed Pharmaceuticals saw a drop in short interest during the month of November. As of November 30th, there was short interest totaling 299,500 shares, a drop of 4.6% from the previous total of 313,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Oramed Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oramed Pharmaceuticals: Cryoport, Inc. (5.25%), Neurogene Inc. (10.22%), biote Corp. (2.29%), Design Therapeutics, Inc. (8.63%), Voyager Therapeutics, Inc. (4.69%), Contineum Therapeutics, Inc. (7.40%), Procaps Group S.A. (0.22%), Acelyrin, Inc. (7.83%), Kamada Ltd. (0.08%), Canopy Growth Co. (9.13%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Oramed Pharmaceuticals stock? Short selling ORMP is an investing strategy that aims to generate trading profit from Oramed Pharmaceuticals as its price is falling. ORMP shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oramed Pharmaceuticals? A short squeeze for Oramed Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ORMP, which in turn drives the price of the stock up even further. How often is Oramed Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ORMP, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies Cryoport Short Interest Data Neurogene Short Interest Data biote Short Interest Data Design Therapeutics Short Interest Data Voyager Therapeutics Short Interest Data Contineum Therapeutics Short Interest Data Procaps Group Short Interest Data Acelyrin Short Interest Data Kamada Short Interest Data Canopy Growth Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ORMP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
